Pulmonary Hypertension

RV Hemodynamics Improved With Riociguat in Pulmonary Arterial Hypertension

RV Hemodynamics Improved With Riociguat in Pulmonary Arterial Hypertension

By

Riociguat was associated with increases in right ventricular work, right ventricular work index, stroke volume index, stroke volume index, and cardiac efficiency in patients with pulmonary arterial hypertension.

High Treprostinil Doses Delay PAH-Related and All-Cause Hospitalizations

High Treprostinil Doses Delay PAH-Related and All-Cause Hospitalizations

By

Higher doses of treprostinil significantly delayed time to first pulmonary arterial hypertension-related or all-cause hospitalization.

Macitentan Tolerated in Portopulmonary Hypertension

Macitentan Tolerated in Portopulmonary Hypertension

By

Recent data suggest that the endothelin receptor antagonist macitentan can be used to target the endothelin pathway in patients with portopulmonary hypertension.

Pulmonary Artery Wedge Pressure and LVEDP Variance in Pulmonary Hypertension

Pulmonary Artery Wedge Pressure and LVEDP Variance in Pulmonary Hypertension

By

In some patients at risk for pulmonary hypertension, left ventricular end diastolic pressure measurement with standard right heart catheterization should be used.

Generic Version of Adcirca Now Available for Pulmonary Arterial Hypertension

Generic Version of Adcirca Now Available for Pulmonary Arterial Hypertension

By

Tadalafil, a phosphodiesterase 5 (PDE5) inhibitor, is indicated to treat pulmonary arterial hypertension to improve exercise ability.

Orenitram Decreased Risk of Morbidity/Mortality Event in PAH Trial

Orenitram Decreased Risk of Morbidity/Mortality Event in PAH Trial

By

United Therapeutics announced that the Phase 3 trial of Orenitram for PAH has met its primary endpoint of delayed time to first clinical worsening event.

Segmental Pulmonary Hypertension: Management of New Classification

Segmental Pulmonary Hypertension: Management of New Classification

By

Segmental pulmonary hypertension can result from several conditions, such as complex pulmonary atresia, hemitruncus arteriosus, absence/atresia of a single pulmonary artery, and an anomalous pulmonary artery from the aorta feeding a single lung segment.

Implantable System for Remodulin Approved for Patients With PAH

Implantable System for Remodulin Approved for Patients With PAH

By

Remodulin is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension.

Supplementing Pulmonary Arterial Hypertension Therapy With Nutritional Changes

Supplementing Pulmonary Arterial Hypertension Therapy With Nutritional Changes

By

Current research suggests patients with pulmonary arterial hypertension may benefit from iron and vitamin D supplementation.

Early Pulmonary Vascular Disease Onset Risk in Adults Born Preterm

Early Pulmonary Vascular Disease Onset Risk in Adults Born Preterm

By

Increased pulmonary pressures, right ventricular dysfunction, and a stiffer pulmonary vascular bed were typical characteristics of early pulmonary vascular disease onset in young adults who were born preterm.

Neopterin as a Potential Biomarker in PAH and Inoperable CTEPH

Neopterin as a Potential Biomarker in PAH and Inoperable CTEPH

By

Neopterin was predictive of clinical deterioration in patients with pulmonary arterial hypertension and inoperable CTEPH.

PAH Mortality Rates Comparable With ERA or PDE5 Inhibitor Therapy

PAH Mortality Rates Comparable With ERA or PDE5 Inhibitor Therapy

By

Although there were no significant differences in pulmonary arterial hypertension survival based on therapy type, age was an important modifier.

Pulmonary Arterial Stiffness Related to mPAP and Heart Rate in Idiopathic PAH

Pulmonary Arterial Stiffness Related to mPAP and Heart Rate in Idiopathic PAH

By

Pulmonary arterial stiffness was related to mean pulmonary arterial pressure and heart rate in patients with untreated idiopathic pulmonary arterial hypertension.

Prognostic Model for Mortality in Pediatric Pulmonary Hypertension

Prognostic Model for Mortality in Pediatric Pulmonary Hypertension

By

The Pediatric Index Pulmonary Hypertension Intensive Care Mortality model was compared with the Pediatric Risk of Mortality 2 and 3 models to determine the best model for predicting mortality.

RV Trabecular Complexity Fractal Analysis: Measuring Remodeling in PH

RV Trabecular Complexity Fractal Analysis: Measuring Remodeling in PH

By

The fractal dimension of right ventricular trabecular complexity was a good reproducible marker of remodeling in pulmonary hypertension.

RV Base/Apex Ratio May Help Diagnose Pulmonary Arterial Hypertension in Children

RV Base/Apex Ratio May Help Diagnose Pulmonary Arterial Hypertension in Children

By

Right ventricular base/apex ratio reference values may help clinicians diagnose children with pulmonary arterial hypertension.

Pregnancy in Pulmonary Arterial Hypertension: Improved Patient Counseling Needed

Pregnancy in Pulmonary Arterial Hypertension: Improved Patient Counseling Needed

By

Many healthcare providers reported that they often do not have the time to counsel their patients with pulmonary arterial hypertension on pregnancy risks.

PAH in Congenital Heart Disease: Challenges and Advances

PAH in Congenital Heart Disease: Challenges and Advances

By

Management strategies were discussed for subtypes of PAH-congenital heart disease including Eisenmenger syndrome, PAH with persistent systemic to pulmonary shunts, and PAH with small or coincidental defect or PAH after defect closure.

Worsening Shortness of Breath in Patient With Hypertension, Afib

Worsening Shortness of Breath in Patient With Hypertension, Afib

By

A 72-year-old man with hypertension and paroxysmal atrial fibrillation presents to the emergency department because he has been experiencing worsening shortness of breath.

Cyanosis From PH or Congenital Heart Disease Responds Well to IV Ferrous Carboxymaltose

Cyanosis From PH or Congenital Heart Disease Responds Well to IV Ferrous Carboxymaltose

By

After iron supplementation, patients with cyanosis experienced significant improvements in hemoglobin concentration, hematocrit, mean corpuscular volume, ferritin, and transferrin saturation.

Venoarterial ECMO Improves Survival to Transplant in Interstitial Lung Disease

Venoarterial ECMO Improves Survival to Transplant in Interstitial Lung Disease

In patients with end-stage interstitial lung disease, there was a higher rate of survival to transplantation with venoarterial extracorporeal membrane oxygenation.

Oxygen Therapy Affects Health-Related QoL in Pulmonary Hypertension

Oxygen Therapy Affects Health-Related QoL in Pulmonary Hypertension

By

Strong relationships were observed between health-related quality-of-life scores and factors such as breathlessness, fatigue, depression, anxiety, and sleep in pulmonary hypertension.

Double Lung Transplantation Improves Survival in Interstitial Pulmonary Fibrosis

Double Lung Transplantation Improves Survival in Interstitial Pulmonary Fibrosis

Double lung transplantation appears to offer superior survival outcomes to single lung transplantation in patients with interstitial pulmonary fibrosis who are younger than 70 years.

Age-Obesity Interaction in Pulmonary Arterial Hypertension

Age-Obesity Interaction in Pulmonary Arterial Hypertension

The interaction of age and obesity with respect to survival in pulmonary arterial hypertension showed an increased risk for mortality in young adults who were morbidly obese.

PAH in Systemic Sclerosis Increases Risk for Early Mortality

PAH in Systemic Sclerosis Increases Risk for Early Mortality

By

The majority of deaths in patients with systemic sclerosis-associated pulmonary arterial hypertension occurred within 4 years of diagnosis.

CTEPH Increases Risk for Sleep Disordered Breathing

CTEPH Increases Risk for Sleep Disordered Breathing

By

Precapillary pulmonary hypertension and obstructive sleep apnea may be causative factors for central sleep apnea and pulmonary hypertension, respectively.

Sildenafil, Bosentan Combination vs Sildenafil Monotherapy in SSc-Associated PAH

Sildenafil, Bosentan Combination vs Sildenafil Monotherapy in SSc-Associated PAH

By

There was no significant difference in efficacy between sildenafil and bosentan initial combination therapy and sildenafil monotherapy in patients with systemic sclerosis-related pulmonary arterial hypertension.

Clinical Trials in PAH: Interpreting Risk Reduction With Caution

Clinical Trials in PAH: Interpreting Risk Reduction With Caution

By

Researchers raise issues regarding interpretation of clinical trial results in the field of pulmonary arterial hypertension.

PAH Pulmonary Hemodynamics Improved With Optimized Iloprost Delivery

PAH Pulmonary Hemodynamics Improved With Optimized Iloprost Delivery

By

Researchers modified the inhalation technique of iloprost in a patient with pulmonary arterial hypertension by attaching a nasal cannula to the inhalator's inlet port, shortening the administration duration.

Improved Pulmonary Arterial Hypertension Risk Prediction Tools Needed

Improved Pulmonary Arterial Hypertension Risk Prediction Tools Needed

By

The use of a risk calculator aimed at achieving a low-risk profile in PAH trials is discussed.

Sign Up for Free e-newsletters